Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2019-05-24
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide and pidilizumab
and to see how well they work in treating patients with multiple myeloma that has come back
(relapsed) or has not responded to treatment (refractory). Biological therapies, such as
lenalidomide, may stimulate the immune system in different ways and stop cancer cells from
growing. Monoclonal antibodies, such as pidilizumab, can block cancer growth by blocking the
ability of cancer to grow and spread. Giving lenalidomide with pidilizumab may work better in
treating relapsed or refractory multiple myeloma.